Inari Medical has raised $27 million to support commercialization of devices for removing large clots from big vessels. New investor Gilde Healthcare led the round with the support of Versant Ventures and all of Inari’s other existing backers.
Irvine, California-based Inari won FDA approval of its second clot removal device, ClotTriever, last year. That gave Inari a portfolio of two catheter-based technologies for treating venous thromboembolism. And, with the commercial opportunities available to the firm increasing, it has pulled in its biggest round to date to fuel a sales and marketing push.
Those efforts could also benefit from clinical development efforts Inari is undertaking. Inari enrolled the last patient in a study of its FlowTriever device in patients with pulmonary embolism last year. The study is listed as completed on ClinicalTrials.gov but Inari is yet to share data.
A positive outcome would strength Inari’s hand as it sets about trying to grow sales of the device. A major market awaits Inari if it can gain traction.
“There is a significant need to improve outcomes for the millions of patients suffering from VTE,” Gilde’s Geoff Pardo said in a statement. “We have been impressed by the Inari team, the progress they've made to date and their vision to transform the treatment of VTE."
Gilde is the new name in a round that reunited the syndicate that powered Inari to a $12.4 million series B round in 2015. Prior to that, Inari funded its progress using the $4.7 million it secured in a round co-led by Versant. The series A followed a period of incubation within Inceptus Medical’s hothouse for medical device startups.